Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
7MB
[thumbnail of Supplemental Information] Other (Supplemental Information)
71MB

Item Type:Article
Title:Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer
Creators Name:Saini, M., Schmidleitner, L., Moreno, H.D., Donato, E., Falcone, M., Bartsch, J.M., Vogel, V., Würth, R., Pfarr, N., Espinet, E., Lehmann, M., Königshoff, M., Reitberger, M., Haas, S., Graf, E., Schwarzmayr, T., Strom, T.M., Spaich, S., Sütterlin, M., Schneeweiss, A., Weichert, W., Schotta, G., Reichert, M., Aceto, N., Sprick, M.R., Trumpp, A., Scheel, C.H. and Klein, C.
Abstract:The acquisition of mesenchymal traits is considered a hallmark of breast cancer progression. However, the functional relevance of epithelial-to-mesenchymal transition (EMT) remains controversial and context dependent. Here, we isolate epithelial and mesenchymal populations from human breast cancer metastatic biopsies and assess their functional potential in vivo. Strikingly, progressively decreasing epithelial cell adhesion molecule (EPCAM) levels correlate with declining disease propagation. Mechanistically, we find that persistent EPCAM expression marks epithelial clones that resist EMT induction and propagate competitively. In contrast, loss of EPCAM defines clones arrested in a mesenchymal state, with concomitant suppression of tumorigenicity and metastatic potential. This dichotomy results from distinct clonal trajectories impacting global epigenetic programs that are determined by the interplay between human ZEB1 and its target GRHL2. Collectively, our results indicate that susceptibility to irreversible EMT restrains clonal propagation, whereas resistance to mesenchymal reprogramming sustains disease spread in multiple models of human metastatic breast cancer, including patient-derived cells in vivo.
Keywords:EPCAM, EMT, ZEB1, GRHL2, Breast Cancer, Metastasis, Intratumor Heterogeneity
Source:Cell Reports
ISSN:2211-1247
Publisher:Cell Press / Elsevier
Volume:42
Number:6
Page Range:112533
Date:27 June 2023
Official Publication:https://doi.org/10.1016/j.celrep.2023.112533
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library